Regarding individuals with idiopathic SVT, the conference highlighted specific recommendations for initiating the diagnostic evaluation of an underlying MPN, starting with screening for the JAK2 V617F mutation in the peripheral blood. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.